imiquimod has been researched along with Endothelioma, Vascular in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ishiuji, Y; Nakagawa, H; Nobeyama, Y | 1 |
Gugneja, S; Miller, R; Neuschler, E; Neuschler, N; Paller, AS; Puscasiu, E; Sidbury, R; Sun, P; Tomai, M; Wang, XQ | 1 |
1 review(s) available for imiquimod and Endothelioma, Vascular
Article | Year |
---|---|
Retiform hemangioendothelioma treated with conservative therapy: report of a case and review of the literature.
Topics: Administration, Cutaneous; Aged; Aminoquinolines; Antineoplastic Agents; Glucocorticoids; Hemangioendothelioma; Humans; Imiquimod; Injections, Intralesional; Lasers, Dye; Male; Nose Neoplasms; Skin Neoplasms; Triamcinolone Acetonide | 2016 |
1 other study(ies) available for imiquimod and Endothelioma, Vascular
Article | Year |
---|---|
Topically applied imiquimod inhibits vascular tumor growth in vivo.
Topics: Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Female; Hemangioendothelioma; Imiquimod; Matrix Metalloproteinase 9; Mice; Proliferating Cell Nuclear Antigen; Tissue Inhibitor of Metalloproteinase-1 | 2003 |